152 related articles for article (PubMed ID: 6897857)
1. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
[TBL] [Abstract][Full Text] [Related]
2. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy of advanced Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
Mizunuma N; Ogawa M; Kuraishi Y; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Itami S
Rinsho Ketsueki; 1991 Nov; 32(11):1410-5. PubMed ID: 1758048
[TBL] [Abstract][Full Text] [Related]
4. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
5. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
6. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
7. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
[TBL] [Abstract][Full Text] [Related]
8. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
9. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease].
Herold M; Anger G; Höche D; Kästner R
Med Klin (Munich); 1987 May; 82(10):345-9. PubMed ID: 2439886
[No Abstract] [Full Text] [Related]
12. [Treatment of Hodgkin's disease with alternately used drug combinations CVPP/ABVD].
Gabryś K; Sciborski R; Kotlarek-Haus S
Przegl Lek; 1988; 45(10):717-20. PubMed ID: 2469104
[No Abstract] [Full Text] [Related]
13. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
14. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
15. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
Glick JH; Barnes JM; Bakemeier RF; Prosnitz LR; Bennett JM; Neiman RS; Costello W; Orlow EL
Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087
[TBL] [Abstract][Full Text] [Related]
17. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
18. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
Tsushita K; Utsumi M; Shimoyama M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin's disease in childhood: therapy results in Argentina.
Sackmann-Muriel F; Bonesana AC; Pavlovsky S; Papendieck C; Morgenfeld M; Penchansky L; Schwartz L; Kvicala R; Sica M; Ojeda F
Am J Pediatr Hematol Oncol; 1981; 3(3):247-54. PubMed ID: 7025683
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
